<?xml version="1.0" encoding="utf-8" standalone="yes" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Raunak Shrestha</title>
    <link>/authors/admin/</link>
    <description>Recent content on Raunak Shrestha</description>
    <generator>Source Themes academia (https://sourcethemes.com/academic/)</generator>
    <language>en-us</language>
    <copyright>Copyright &amp;copy; {year} Raunak Shrestha</copyright>
    <lastBuildDate>Fri, 01 Nov 2024 00:00:00 +0000</lastBuildDate>
    
	    <atom:link href="/authors/admin/index.xml" rel="self" type="application/rss+xml" />
    
    
    <item>
      <title></title>
      <link>/authors/admin/</link>
      <pubDate>Fri, 01 Nov 2024 00:00:00 +0000</pubDate>
      
      <guid>/authors/admin/</guid>
      <description>&lt;p&gt;I am a Computational Biology Research Scientist with &lt;a href=&#34;http://fenglaboratory.com/&#34;&gt;Dr. Felix Feng&lt;/a&gt; at UCSF. My primary research location is the &lt;a href=&#34;http://cancer.ucsf.edu/&#34;&gt;UCSF HDFC Cancer Center&lt;/a&gt;. Additionally, I hold Adjunct Research Scientist position at the &lt;a href=&#34;https://www.naamii.org.np/&#34;&gt;Nepal Applied Mathematics &amp;amp; Informatics Institute for Research (NAAMII)&lt;/a&gt;, where I am leading the Computational Genomics Laboratory. [&lt;a href=&#34;/bio/&#34;&gt;My Bio&lt;/a&gt;]&lt;/p&gt;
&lt;p&gt;My main interest lies in understanding cancer progression and treatment resistance through the development and application of computational genomics approaches.&lt;/p&gt;
&lt;blockquote&gt;
&lt;p&gt;&lt;strong&gt;I am actively looking for academic faculty position.&lt;/strong&gt;&lt;/p&gt;
&lt;/blockquote&gt;
</description>
    </item>
    
    <item>
      <title>Generalized Extreme Studentized Deviate (GESD) test to detect outliers in R</title>
      <link>/post/gesd/</link>
      <pubDate>Fri, 01 Nov 2024 00:00:00 +0000</pubDate>
      
      <guid>/post/gesd/</guid>
      <description>&lt;blockquote&gt;
&lt;p&gt;The GESD statistical test can be used to answer the following question: &lt;em&gt;How many outliers does the data set contain?&lt;/em&gt;&lt;/p&gt;
&lt;/blockquote&gt;
&lt;p&gt;Here, I present an implementation of GESD test written in R which can be accessed using the following url: &lt;a href=&#34;https://github.com/raunakms/GESD&#34;&gt;https://github.com/raunakms/GESD&lt;/a&gt;&lt;/p&gt;
&lt;h2 id=&#34;generalized-extreme-studentized-deviate-gesd-test&#34;&gt;Generalized Extreme Studentized Deviate (GESD) test&lt;/h2&gt;
&lt;p&gt;The generalized (extreme Studentized deviate) ESD test (Rosner 1983) is a statistical method used to detect one or more outliers in a univariate data set that follows an approximately normal distribution. The primary limitation of the Grubbs test and the Tietjen-Moore test is that the suspected number of outliers, $k$, must be specified exactly. If $k$ is not specified correctly, this can distort the conclusions of these tests. On the other hand, the generalized ESD test (Rosner 1983) only requires that an upper bound for the suspected number of outliers be specified.&lt;/p&gt;
&lt;p&gt;Given the upper bound, $r$, the generalized ESD test essentially performs $r$ separate tests: a test for one outlier, a test for two outliers, and so on up to $r$ outliers.&lt;/p&gt;
&lt;ul&gt;
&lt;li&gt;The generalized ESD test is defined for the hypothesis:
&lt;ul&gt;
&lt;li&gt;$H_{0}$: There are no outliers in the data set&lt;/li&gt;
&lt;li&gt;$H_{a}$: There are up to r outliers in the data set&lt;/li&gt;
&lt;/ul&gt;
&lt;/li&gt;
&lt;/ul&gt;
&lt;p&gt;&lt;strong&gt;Test Statistic&lt;/strong&gt;: Compute
$$R_{i} = \frac{max_{i}|x_{i} - \bar{x}|}{s} $$
with $x$ and $s$ denoting the sample mean and sample standard deviation, respectively. Remove the observation that maximizes $|x_{i} - \bar{x}|$ and then recompute the above statistic with $n-1$ observations. Repeat this process until $r$ observations have been removed. This results in the $r$ test statistics $R_{1}, R_{2}, &amp;hellip;, R_{r}$.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Significance Level&lt;/strong&gt;: alpha $(\alpha)$&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Critical Region&lt;/strong&gt;: Corresponding to the $r$ test statistics, compute the following $r$ critical values
$$ \lambda_{i} = \frac{(n-i) * t_{n-i-1,p}}{ \sqrt{(n-i-1 + t^2_{n-i-1,p})*(n-i+1)} } $$&lt;/p&gt;
&lt;p&gt;where $i = 1, 2, &amp;hellip;, r$, and $t_{d,p}$ is the $p^{th}$ percentile of a $t$ distribution with $d$ degrees of freedom.&lt;/p&gt;
&lt;p&gt;$$ p = 1 - \frac{\alpha}{2*(n-i+1)} $$&lt;/p&gt;
&lt;p&gt;The number of outliers is determined by finding the largest $i$ such that $ R_{i} &amp;gt; \lambda_{i} $. Simulation studies by Rosner indicate that this critical value approximation is very accurate for $n \ge 25$ and reasonably accurate for $n \ge 15$.&lt;/p&gt;
&lt;p&gt;Note that although the generalized ESD is essentially Grubbs test applied sequentially, there are a few important distinctions:&lt;/p&gt;
&lt;ul&gt;
&lt;li&gt;The generalized ESD test makes appropriate adjustments for the critical values based on the number of outliers being tested for that the sequential application of Grubbs test does not.&lt;/li&gt;
&lt;li&gt;If there is significant masking, applying Grubbs test sequentially may stop too soon. The example below identifies three outliers at the 5% level when using the generalized ESD test.&lt;/li&gt;
&lt;li&gt;However, trying to use Grubbs test sequentially would stop at the first iteration and declare no outliers.&lt;/li&gt;
&lt;/ul&gt;
&lt;h2 id=&#34;original-paper-citation&#34;&gt;Original Paper Citation&lt;/h2&gt;
&lt;ul&gt;
&lt;li&gt;B. Rosner (1983). Percentage Points for a Generalized ESD Many-Outlier Procedure. Technometrics 25(2), pp. 165-172. &lt;a href=&#34;http://www.jstor.org/stable/1268549?seq=1&#34;&gt;http://www.jstor.org/stable/1268549?seq=1&lt;/a&gt;&lt;/li&gt;
&lt;/ul&gt;
&lt;hr&gt;
&lt;h2 id=&#34;decription&#34;&gt;Decription&lt;/h2&gt;
&lt;p&gt;Computes outliers for the given data using GESD statistics.&lt;/p&gt;
&lt;h3 id=&#34;usage&#34;&gt;Usage&lt;/h3&gt;
&lt;pre tabindex=&#34;0&#34;&gt;&lt;code&gt;gesd(obs, alpha, value.zscore, r)
&lt;/code&gt;&lt;/pre&gt;&lt;h3 id=&#34;arguments&#34;&gt;Arguments&lt;/h3&gt;
&lt;ul&gt;
&lt;li&gt;$obs$ : a vector of observation&lt;/li&gt;
&lt;li&gt;$alpha$ : significance Level&lt;/li&gt;
&lt;li&gt;$value.zscore$ : if the observation value are already z-normalized. Takes values &amp;ldquo;YES&amp;rdquo; or &amp;ldquo;NO&amp;rdquo;.&lt;/li&gt;
&lt;li&gt;$r$ : upperbound to the number of observations to call as an outlier. If NA, computes GESD test statistic until values of half sample size have been removed from the sample.&lt;/li&gt;
&lt;/ul&gt;
&lt;h3 id=&#34;value&#34;&gt;Value&lt;/h3&gt;
&lt;ul&gt;
&lt;li&gt;Total : The first column gives the total number of outliers&lt;/li&gt;
&lt;li&gt;Rest of the columns are for each observation&lt;/li&gt;
&lt;li&gt;Value of the outlier indicates the outlier rank in the acending order where 0 inidicates not an outlier, 1 inidicate the highest ranked outlier (i.e. most extreme observation).&lt;/li&gt;
&lt;/ul&gt;
&lt;hr&gt;
&lt;h2 id=&#34;r-code&#34;&gt;R-code&lt;/h2&gt;
&lt;p&gt;Below is the R-code of the function that implements GESD test&lt;/p&gt;
&lt;div class=&#34;highlight&#34;&gt;&lt;pre tabindex=&#34;0&#34; style=&#34;color:#f8f8f2;background-color:#272822;-moz-tab-size:4;-o-tab-size:4;tab-size:4;&#34;&gt;&lt;code class=&#34;language-R&#34; data-lang=&#34;R&#34;&gt;&lt;span style=&#34;display:flex;&#34;&gt;&lt;span&gt;gesd &lt;span style=&#34;color:#f92672&#34;&gt;&amp;lt;-&lt;/span&gt; &lt;span style=&#34;color:#66d9ef&#34;&gt;function&lt;/span&gt;(obs, alpha, value.zscore&lt;span style=&#34;color:#f92672&#34;&gt;=&lt;/span&gt;&lt;span style=&#34;color:#66d9ef&#34;&gt;NA&lt;/span&gt;, r&lt;span style=&#34;color:#f92672&#34;&gt;=&lt;/span&gt;&lt;span style=&#34;color:#66d9ef&#34;&gt;NA&lt;/span&gt;) {
&lt;/span&gt;&lt;/span&gt;&lt;span style=&#34;display:flex;&#34;&gt;&lt;span&gt;	&lt;span style=&#34;color:#75715e&#34;&gt;#### Define and Declare Variables ####&lt;/span&gt;
&lt;/span&gt;&lt;/span&gt;&lt;span style=&#34;display:flex;&#34;&gt;&lt;span&gt;	n &lt;span style=&#34;color:#f92672&#34;&gt;&amp;lt;-&lt;/span&gt; &lt;span style=&#34;color:#a6e22e&#34;&gt;length&lt;/span&gt;(obs)
&lt;/span&gt;&lt;/span&gt;&lt;span style=&#34;display:flex;&#34;&gt;&lt;span&gt;	&lt;span style=&#34;color:#66d9ef&#34;&gt;if&lt;/span&gt;(&lt;span style=&#34;color:#a6e22e&#34;&gt;is.na&lt;/span&gt;(r)){r &lt;span style=&#34;color:#f92672&#34;&gt;&amp;lt;-&lt;/span&gt; &lt;span style=&#34;color:#a6e22e&#34;&gt;floor&lt;/span&gt;(n&lt;span style=&#34;color:#f92672&#34;&gt;/&lt;/span&gt;&lt;span style=&#34;color:#ae81ff&#34;&gt;2&lt;/span&gt;)} &lt;span style=&#34;color:#75715e&#34;&gt;# by default, set upper bound on number of outliers &amp;#39;r&amp;#39; to 1/2 sample size&lt;/span&gt;
&lt;/span&gt;&lt;/span&gt;&lt;span style=&#34;display:flex;&#34;&gt;&lt;span&gt;	R &lt;span style=&#34;color:#f92672&#34;&gt;&amp;lt;-&lt;/span&gt; &lt;span style=&#34;color:#a6e22e&#34;&gt;numeric&lt;/span&gt;(length&lt;span style=&#34;color:#f92672&#34;&gt;=&lt;/span&gt;r) &lt;span style=&#34;color:#75715e&#34;&gt;# test statistics for &amp;#39;r&amp;#39; outliers&lt;/span&gt;
&lt;/span&gt;&lt;/span&gt;&lt;span style=&#34;display:flex;&#34;&gt;&lt;span&gt;	lambda &lt;span style=&#34;color:#f92672&#34;&gt;&amp;lt;-&lt;/span&gt; &lt;span style=&#34;color:#a6e22e&#34;&gt;numeric&lt;/span&gt;(length&lt;span style=&#34;color:#f92672&#34;&gt;=&lt;/span&gt;r) &lt;span style=&#34;color:#75715e&#34;&gt;# critical values for &amp;#39;r&amp;#39; outliers&lt;/span&gt;
&lt;/span&gt;&lt;/span&gt;&lt;span style=&#34;display:flex;&#34;&gt;&lt;span&gt;	outlier_ind &lt;span style=&#34;color:#f92672&#34;&gt;&amp;lt;-&lt;/span&gt; &lt;span style=&#34;color:#a6e22e&#34;&gt;numeric&lt;/span&gt;(length&lt;span style=&#34;color:#f92672&#34;&gt;=&lt;/span&gt;r) &lt;span style=&#34;color:#75715e&#34;&gt;# removed outlier observation values&lt;/span&gt;
&lt;/span&gt;&lt;/span&gt;&lt;span style=&#34;display:flex;&#34;&gt;&lt;span&gt;	outlier_val &lt;span style=&#34;color:#f92672&#34;&gt;&amp;lt;-&lt;/span&gt; &lt;span style=&#34;color:#a6e22e&#34;&gt;numeric&lt;/span&gt;(length&lt;span style=&#34;color:#f92672&#34;&gt;=&lt;/span&gt;r) &lt;span style=&#34;color:#75715e&#34;&gt;# removed outlier observation values&lt;/span&gt;
&lt;/span&gt;&lt;/span&gt;&lt;span style=&#34;display:flex;&#34;&gt;&lt;span&gt;	m &lt;span style=&#34;color:#f92672&#34;&gt;&amp;lt;-&lt;/span&gt; &lt;span style=&#34;color:#ae81ff&#34;&gt;0&lt;/span&gt; &lt;span style=&#34;color:#75715e&#34;&gt;# number of outliers&lt;/span&gt;
&lt;/span&gt;&lt;/span&gt;&lt;span style=&#34;display:flex;&#34;&gt;&lt;span&gt;	obs_new &lt;span style=&#34;color:#f92672&#34;&gt;&amp;lt;-&lt;/span&gt; obs &lt;span style=&#34;color:#75715e&#34;&gt;# temporary observation values&lt;/span&gt;
&lt;/span&gt;&lt;/span&gt;&lt;span style=&#34;display:flex;&#34;&gt;&lt;span&gt;	
&lt;/span&gt;&lt;/span&gt;&lt;span style=&#34;display:flex;&#34;&gt;&lt;span&gt;	&lt;span style=&#34;color:#75715e&#34;&gt;#### Find outliers ####&lt;/span&gt;
&lt;/span&gt;&lt;/span&gt;&lt;span style=&#34;display:flex;&#34;&gt;&lt;span&gt;	&lt;span style=&#34;color:#66d9ef&#34;&gt;for&lt;/span&gt;(i &lt;span style=&#34;color:#66d9ef&#34;&gt;in&lt;/span&gt; &lt;span style=&#34;color:#ae81ff&#34;&gt;1&lt;/span&gt;&lt;span style=&#34;color:#f92672&#34;&gt;:&lt;/span&gt;r){
&lt;/span&gt;&lt;/span&gt;&lt;span style=&#34;display:flex;&#34;&gt;&lt;span&gt;	
&lt;/span&gt;&lt;/span&gt;&lt;span style=&#34;display:flex;&#34;&gt;&lt;span&gt;		&lt;span style=&#34;color:#75715e&#34;&gt;#### Compute test statistic ####&lt;/span&gt;
&lt;/span&gt;&lt;/span&gt;&lt;span style=&#34;display:flex;&#34;&gt;&lt;span&gt;		&lt;span style=&#34;color:#66d9ef&#34;&gt;if&lt;/span&gt;((value.zscore &lt;span style=&#34;color:#f92672&#34;&gt;==&lt;/span&gt; &lt;span style=&#34;color:#e6db74&#34;&gt;&amp;#34;YES&amp;#34;&lt;/span&gt;) &lt;span style=&#34;color:#f92672&#34;&gt;|&lt;/span&gt; (value.zscore &lt;span style=&#34;color:#f92672&#34;&gt;==&lt;/span&gt; &lt;span style=&#34;color:#e6db74&#34;&gt;&amp;#34;Y&amp;#34;&lt;/span&gt;)){
&lt;/span&gt;&lt;/span&gt;&lt;span style=&#34;display:flex;&#34;&gt;&lt;span&gt;			z &lt;span style=&#34;color:#f92672&#34;&gt;&amp;lt;-&lt;/span&gt; &lt;span style=&#34;color:#a6e22e&#34;&gt;abs&lt;/span&gt;(obs_new) &lt;span style=&#34;color:#75715e&#34;&gt;# If Z-score is alrealy computed&lt;/span&gt;
&lt;/span&gt;&lt;/span&gt;&lt;span style=&#34;display:flex;&#34;&gt;&lt;span&gt;		}&lt;span style=&#34;color:#66d9ef&#34;&gt;else&lt;/span&gt; &lt;span style=&#34;color:#66d9ef&#34;&gt;if&lt;/span&gt;((value.zscore &lt;span style=&#34;color:#f92672&#34;&gt;==&lt;/span&gt; &lt;span style=&#34;color:#e6db74&#34;&gt;&amp;#34;NO&amp;#34;&lt;/span&gt;) &lt;span style=&#34;color:#f92672&#34;&gt;|&lt;/span&gt; (value.zscore &lt;span style=&#34;color:#f92672&#34;&gt;==&lt;/span&gt; &lt;span style=&#34;color:#e6db74&#34;&gt;&amp;#34;N&amp;#34;&lt;/span&gt;)){
&lt;/span&gt;&lt;/span&gt;&lt;span style=&#34;display:flex;&#34;&gt;&lt;span&gt;			z &lt;span style=&#34;color:#f92672&#34;&gt;&amp;lt;-&lt;/span&gt; &lt;span style=&#34;color:#a6e22e&#34;&gt;abs&lt;/span&gt;(obs_new &lt;span style=&#34;color:#f92672&#34;&gt;-&lt;/span&gt; &lt;span style=&#34;color:#a6e22e&#34;&gt;mean&lt;/span&gt;(obs_new))&lt;span style=&#34;color:#f92672&#34;&gt;/&lt;/span&gt;&lt;span style=&#34;color:#a6e22e&#34;&gt;sd&lt;/span&gt;(obs_new) &lt;span style=&#34;color:#75715e&#34;&gt;# Z-scores&lt;/span&gt;
&lt;/span&gt;&lt;/span&gt;&lt;span style=&#34;display:flex;&#34;&gt;&lt;span&gt;		} &lt;span style=&#34;color:#66d9ef&#34;&gt;else&lt;/span&gt;{
&lt;/span&gt;&lt;/span&gt;&lt;span style=&#34;display:flex;&#34;&gt;&lt;span&gt;			&lt;span style=&#34;color:#a6e22e&#34;&gt;print&lt;/span&gt;(&lt;span style=&#34;color:#e6db74&#34;&gt;&amp;#34;ERROR! Inappropriate value for value.score=[YES|NO]&amp;#34;&lt;/span&gt;)
&lt;/span&gt;&lt;/span&gt;&lt;span style=&#34;display:flex;&#34;&gt;&lt;span&gt;		}
&lt;/span&gt;&lt;/span&gt;&lt;span style=&#34;display:flex;&#34;&gt;&lt;span&gt;		
&lt;/span&gt;&lt;/span&gt;&lt;span style=&#34;display:flex;&#34;&gt;&lt;span&gt;		max_ind &lt;span style=&#34;color:#f92672&#34;&gt;&amp;lt;-&lt;/span&gt; &lt;span style=&#34;color:#a6e22e&#34;&gt;which&lt;/span&gt;(z&lt;span style=&#34;color:#f92672&#34;&gt;==&lt;/span&gt;&lt;span style=&#34;color:#a6e22e&#34;&gt;max&lt;/span&gt;(z),arr.ind&lt;span style=&#34;color:#f92672&#34;&gt;=&lt;/span&gt;T)[1] &lt;span style=&#34;color:#75715e&#34;&gt;# in case of ties, return first one&lt;/span&gt;
&lt;/span&gt;&lt;/span&gt;&lt;span style=&#34;display:flex;&#34;&gt;&lt;span&gt;		R[i] &lt;span style=&#34;color:#f92672&#34;&gt;&amp;lt;-&lt;/span&gt; z[max_ind] &lt;span style=&#34;color:#75715e&#34;&gt;# max Z-score&lt;/span&gt;
&lt;/span&gt;&lt;/span&gt;&lt;span style=&#34;display:flex;&#34;&gt;&lt;span&gt;		outlier_val[i] &lt;span style=&#34;color:#f92672&#34;&gt;&amp;lt;-&lt;/span&gt; obs_new[max_ind] &lt;span style=&#34;color:#75715e&#34;&gt;# removed outlier observation values&lt;/span&gt;
&lt;/span&gt;&lt;/span&gt;&lt;span style=&#34;display:flex;&#34;&gt;&lt;span&gt;		outlier_ind[i] &lt;span style=&#34;color:#f92672&#34;&gt;&amp;lt;-&lt;/span&gt; &lt;span style=&#34;color:#a6e22e&#34;&gt;which&lt;/span&gt;(obs_new[max_ind] &lt;span style=&#34;color:#f92672&#34;&gt;==&lt;/span&gt; obs, arr.ind&lt;span style=&#34;color:#f92672&#34;&gt;=&lt;/span&gt;T)[1] &lt;span style=&#34;color:#75715e&#34;&gt;# index of removed outlier observation values&lt;/span&gt;
&lt;/span&gt;&lt;/span&gt;&lt;span style=&#34;display:flex;&#34;&gt;&lt;span&gt;		obs_new &lt;span style=&#34;color:#f92672&#34;&gt;&amp;lt;-&lt;/span&gt; obs_new[&lt;span style=&#34;color:#f92672&#34;&gt;-&lt;/span&gt;max_ind] &lt;span style=&#34;color:#75715e&#34;&gt;# remove observation that maximizes |x_i - x_mean|&lt;/span&gt;
&lt;/span&gt;&lt;/span&gt;&lt;span style=&#34;display:flex;&#34;&gt;&lt;span&gt;		
&lt;/span&gt;&lt;/span&gt;&lt;span style=&#34;display:flex;&#34;&gt;&lt;span&gt;		&lt;span style=&#34;color:#75715e&#34;&gt;#### Compute critical values ####&lt;/span&gt;
&lt;/span&gt;&lt;/span&gt;&lt;span style=&#34;display:flex;&#34;&gt;&lt;span&gt;		&lt;span style=&#34;color:#75715e&#34;&gt;##n_obs &amp;lt;- length(obs_new) # subset sample size&lt;/span&gt;
&lt;/span&gt;&lt;/span&gt;&lt;span style=&#34;display:flex;&#34;&gt;&lt;span&gt;		p &lt;span style=&#34;color:#f92672&#34;&gt;&amp;lt;-&lt;/span&gt; &lt;span style=&#34;color:#ae81ff&#34;&gt;1&lt;/span&gt; &lt;span style=&#34;color:#f92672&#34;&gt;-&lt;/span&gt; alpha&lt;span style=&#34;color:#f92672&#34;&gt;/&lt;/span&gt;(&lt;span style=&#34;color:#ae81ff&#34;&gt;2&lt;/span&gt;&lt;span style=&#34;color:#f92672&#34;&gt;*&lt;/span&gt;(n&lt;span style=&#34;color:#f92672&#34;&gt;-&lt;/span&gt;i&lt;span style=&#34;color:#ae81ff&#34;&gt;+1&lt;/span&gt;)) &lt;span style=&#34;color:#75715e&#34;&gt;# probability&lt;/span&gt;
&lt;/span&gt;&lt;/span&gt;&lt;span style=&#34;display:flex;&#34;&gt;&lt;span&gt;		t_pv &lt;span style=&#34;color:#f92672&#34;&gt;&amp;lt;-&lt;/span&gt; &lt;span style=&#34;color:#a6e22e&#34;&gt;qt&lt;/span&gt;(p,df&lt;span style=&#34;color:#f92672&#34;&gt;=&lt;/span&gt;(n&lt;span style=&#34;color:#f92672&#34;&gt;-&lt;/span&gt;i&lt;span style=&#34;color:#ae81ff&#34;&gt;-1&lt;/span&gt;)) &lt;span style=&#34;color:#75715e&#34;&gt;# Critical value from Student&amp;#39;s t distribution&lt;/span&gt;
&lt;/span&gt;&lt;/span&gt;&lt;span style=&#34;display:flex;&#34;&gt;&lt;span&gt;		lambda[i] &lt;span style=&#34;color:#f92672&#34;&gt;&amp;lt;-&lt;/span&gt; ((n&lt;span style=&#34;color:#f92672&#34;&gt;-&lt;/span&gt;i)&lt;span style=&#34;color:#f92672&#34;&gt;*&lt;/span&gt;t_pv) &lt;span style=&#34;color:#f92672&#34;&gt;/&lt;/span&gt; (&lt;span style=&#34;color:#a6e22e&#34;&gt;sqrt&lt;/span&gt;((n&lt;span style=&#34;color:#f92672&#34;&gt;-&lt;/span&gt;i&lt;span style=&#34;color:#ae81ff&#34;&gt;-1&lt;/span&gt;&lt;span style=&#34;color:#f92672&#34;&gt;+&lt;/span&gt;t_pv^2)&lt;span style=&#34;color:#f92672&#34;&gt;*&lt;/span&gt;(n&lt;span style=&#34;color:#f92672&#34;&gt;-&lt;/span&gt;i&lt;span style=&#34;color:#ae81ff&#34;&gt;+1&lt;/span&gt;)))
&lt;/span&gt;&lt;/span&gt;&lt;span style=&#34;display:flex;&#34;&gt;&lt;span&gt;		
&lt;/span&gt;&lt;/span&gt;&lt;span style=&#34;display:flex;&#34;&gt;&lt;span&gt;		&lt;span style=&#34;color:#75715e&#34;&gt;#### Find exact number of outliers: largest &amp;#39;i&amp;#39; such that R_i &amp;gt; lambda_i ####&lt;/span&gt;
&lt;/span&gt;&lt;/span&gt;&lt;span style=&#34;display:flex;&#34;&gt;&lt;span&gt;		&lt;span style=&#34;color:#75715e&#34;&gt;# print(c(i, R[i], lambda[i]))&lt;/span&gt;
&lt;/span&gt;&lt;/span&gt;&lt;span style=&#34;display:flex;&#34;&gt;&lt;span&gt;		&lt;span style=&#34;color:#75715e&#34;&gt;# try ((R[i] &amp;gt; lambda[i]), finally &amp;lt;- print(c(i, R[i], lambda[i]))&lt;/span&gt;
&lt;/span&gt;&lt;/span&gt;&lt;span style=&#34;display:flex;&#34;&gt;&lt;span&gt;		&lt;span style=&#34;color:#75715e&#34;&gt;# )&lt;/span&gt;
&lt;/span&gt;&lt;/span&gt;&lt;span style=&#34;display:flex;&#34;&gt;&lt;span&gt;		&lt;span style=&#34;color:#66d9ef&#34;&gt;if&lt;/span&gt;(&lt;span style=&#34;color:#f92672&#34;&gt;!&lt;/span&gt;&lt;span style=&#34;color:#a6e22e&#34;&gt;is.na&lt;/span&gt;(R[i]) &lt;span style=&#34;color:#f92672&#34;&gt;&amp;amp;&lt;/span&gt; &lt;span style=&#34;color:#f92672&#34;&gt;!&lt;/span&gt;&lt;span style=&#34;color:#a6e22e&#34;&gt;is.na&lt;/span&gt;(lambda[i])) { &lt;span style=&#34;color:#75715e&#34;&gt;# qt can produce NaNs&lt;/span&gt;
&lt;/span&gt;&lt;/span&gt;&lt;span style=&#34;display:flex;&#34;&gt;&lt;span&gt;			&lt;span style=&#34;color:#66d9ef&#34;&gt;if&lt;/span&gt; (R[i] &lt;span style=&#34;color:#f92672&#34;&gt;&amp;gt;&lt;/span&gt; lambda[i]) {
&lt;/span&gt;&lt;/span&gt;&lt;span style=&#34;display:flex;&#34;&gt;&lt;span&gt;				m &lt;span style=&#34;color:#f92672&#34;&gt;&amp;lt;-&lt;/span&gt; i
&lt;/span&gt;&lt;/span&gt;&lt;span style=&#34;display:flex;&#34;&gt;&lt;span&gt;			}
&lt;/span&gt;&lt;/span&gt;&lt;span style=&#34;display:flex;&#34;&gt;&lt;span&gt;			&lt;span style=&#34;color:#75715e&#34;&gt;# else {&lt;/span&gt;
&lt;/span&gt;&lt;/span&gt;&lt;span style=&#34;display:flex;&#34;&gt;&lt;span&gt;				&lt;span style=&#34;color:#75715e&#34;&gt;# break&lt;/span&gt;
&lt;/span&gt;&lt;/span&gt;&lt;span style=&#34;display:flex;&#34;&gt;&lt;span&gt;			&lt;span style=&#34;color:#75715e&#34;&gt;# }&lt;/span&gt;
&lt;/span&gt;&lt;/span&gt;&lt;span style=&#34;display:flex;&#34;&gt;&lt;span&gt;			
&lt;/span&gt;&lt;/span&gt;&lt;span style=&#34;display:flex;&#34;&gt;&lt;span&gt;		}
&lt;/span&gt;&lt;/span&gt;&lt;span style=&#34;display:flex;&#34;&gt;&lt;span&gt;	}
&lt;/span&gt;&lt;/span&gt;&lt;span style=&#34;display:flex;&#34;&gt;&lt;span&gt;
&lt;/span&gt;&lt;/span&gt;&lt;span style=&#34;display:flex;&#34;&gt;&lt;span&gt;	vals &lt;span style=&#34;color:#f92672&#34;&gt;&amp;lt;-&lt;/span&gt; &lt;span style=&#34;color:#a6e22e&#34;&gt;data.frame&lt;/span&gt;(NumOutliers&lt;span style=&#34;color:#f92672&#34;&gt;=&lt;/span&gt;&lt;span style=&#34;color:#ae81ff&#34;&gt;1&lt;/span&gt;&lt;span style=&#34;color:#f92672&#34;&gt;:&lt;/span&gt;r, TestStatistic&lt;span style=&#34;color:#f92672&#34;&gt;=&lt;/span&gt;R, CriticalValue&lt;span style=&#34;color:#f92672&#34;&gt;=&lt;/span&gt;lambda)
&lt;/span&gt;&lt;/span&gt;&lt;span style=&#34;display:flex;&#34;&gt;&lt;span&gt;	&lt;span style=&#34;color:#75715e&#34;&gt;# print(vals)&lt;/span&gt;
&lt;/span&gt;&lt;/span&gt;&lt;span style=&#34;display:flex;&#34;&gt;&lt;span&gt;	
&lt;/span&gt;&lt;/span&gt;&lt;span style=&#34;display:flex;&#34;&gt;&lt;span&gt;	&lt;span style=&#34;color:#75715e&#34;&gt;#### Rank outlier observations ####&lt;/span&gt;
&lt;/span&gt;&lt;/span&gt;&lt;span style=&#34;display:flex;&#34;&gt;&lt;span&gt;	outlier_rank &lt;span style=&#34;color:#f92672&#34;&gt;&amp;lt;-&lt;/span&gt; &lt;span style=&#34;color:#a6e22e&#34;&gt;numeric&lt;/span&gt;(length&lt;span style=&#34;color:#f92672&#34;&gt;=&lt;/span&gt;n)
&lt;/span&gt;&lt;/span&gt;&lt;span style=&#34;display:flex;&#34;&gt;&lt;span&gt;	&lt;span style=&#34;color:#66d9ef&#34;&gt;if&lt;/span&gt; (m &lt;span style=&#34;color:#f92672&#34;&gt;&amp;gt;&lt;/span&gt; &lt;span style=&#34;color:#ae81ff&#34;&gt;0&lt;/span&gt;) {
&lt;/span&gt;&lt;/span&gt;&lt;span style=&#34;display:flex;&#34;&gt;&lt;span&gt;		&lt;span style=&#34;color:#66d9ef&#34;&gt;for&lt;/span&gt; (i &lt;span style=&#34;color:#66d9ef&#34;&gt;in&lt;/span&gt; &lt;span style=&#34;color:#ae81ff&#34;&gt;1&lt;/span&gt;&lt;span style=&#34;color:#f92672&#34;&gt;:&lt;/span&gt;m) {
&lt;/span&gt;&lt;/span&gt;&lt;span style=&#34;display:flex;&#34;&gt;&lt;span&gt;			&lt;span style=&#34;color:#75715e&#34;&gt;# outlier_rank[outlier_ind[i]] &amp;lt;- i&lt;/span&gt;
&lt;/span&gt;&lt;/span&gt;&lt;span style=&#34;display:flex;&#34;&gt;&lt;span&gt;			outlier_rank&lt;span style=&#34;color:#a6e22e&#34;&gt;[which&lt;/span&gt;(obs&lt;span style=&#34;color:#f92672&#34;&gt;==&lt;/span&gt;outlier_val[i])] &lt;span style=&#34;color:#f92672&#34;&gt;&amp;lt;-&lt;/span&gt; i
&lt;/span&gt;&lt;/span&gt;&lt;span style=&#34;display:flex;&#34;&gt;&lt;span&gt;		}
&lt;/span&gt;&lt;/span&gt;&lt;span style=&#34;display:flex;&#34;&gt;&lt;span&gt;	}
&lt;/span&gt;&lt;/span&gt;&lt;span style=&#34;display:flex;&#34;&gt;&lt;span&gt;	num_outliers &lt;span style=&#34;color:#f92672&#34;&gt;&amp;lt;-&lt;/span&gt; &lt;span style=&#34;color:#a6e22e&#34;&gt;sum&lt;/span&gt;(outlier_rank &lt;span style=&#34;color:#f92672&#34;&gt;!=&lt;/span&gt; &lt;span style=&#34;color:#ae81ff&#34;&gt;0&lt;/span&gt;) &lt;span style=&#34;color:#75715e&#34;&gt;#14 and 25 missing&lt;/span&gt;
&lt;/span&gt;&lt;/span&gt;&lt;span style=&#34;display:flex;&#34;&gt;&lt;span&gt;	res &lt;span style=&#34;color:#f92672&#34;&gt;&amp;lt;-&lt;/span&gt; &lt;span style=&#34;color:#a6e22e&#34;&gt;c&lt;/span&gt;(num_outliers, outlier_rank)
&lt;/span&gt;&lt;/span&gt;&lt;span style=&#34;display:flex;&#34;&gt;&lt;span&gt;	&lt;span style=&#34;color:#a6e22e&#34;&gt;names&lt;/span&gt;(res) &lt;span style=&#34;color:#f92672&#34;&gt;&amp;lt;-&lt;/span&gt; &lt;span style=&#34;color:#a6e22e&#34;&gt;c&lt;/span&gt;(&lt;span style=&#34;color:#e6db74&#34;&gt;&amp;#34;Total&amp;#34;&lt;/span&gt;, &lt;span style=&#34;color:#a6e22e&#34;&gt;names&lt;/span&gt;(obs))
&lt;/span&gt;&lt;/span&gt;&lt;span style=&#34;display:flex;&#34;&gt;&lt;span&gt;	
&lt;/span&gt;&lt;/span&gt;&lt;span style=&#34;display:flex;&#34;&gt;&lt;span&gt;	&lt;span style=&#34;color:#66d9ef&#34;&gt;return&lt;/span&gt;(res)	
&lt;/span&gt;&lt;/span&gt;&lt;span style=&#34;display:flex;&#34;&gt;&lt;span&gt;}
&lt;/span&gt;&lt;/span&gt;&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;</description>
    </item>
    
    <item>
      <title>Genomic and transcriptomic features of androgen receptor signaling inhibitor resistance in metastatic castration-resistant prostate cancer</title>
      <link>/publication/2024_prepost/</link>
      <pubDate>Tue, 13 Aug 2024 00:00:00 +0000</pubDate>
      
      <guid>/publication/2024_prepost/</guid>
      <description></description>
    </item>
    
    <item>
      <title>An Atlas of Accessible Chromatin in Advanced Prostate Cancer Reveals the Epigenetic Evolution during Tumor Progression</title>
      <link>/publication/2024_wcdt_atacseq/</link>
      <pubDate>Thu, 11 Jul 2024 00:00:00 +0000</pubDate>
      
      <guid>/publication/2024_wcdt_atacseq/</guid>
      <description>&lt;!-- raw HTML omitted --&gt;
</description>
    </item>
    
    <item>
      <title>Integrated analyses highlight interactions between the three-dimensional genome and DNA, RNA and epigenomic alterations in metastatic prostate cancer</title>
      <link>/publication/2024_wcdt_hic/</link>
      <pubDate>Sun, 09 Jun 2024 00:00:00 +0000</pubDate>
      
      <guid>/publication/2024_wcdt_hic/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Integrative analysis of ultra-deep RNA-seq reveals alternative promoter usage as a mechanism of activating oncogenic programmes during prostate cancer progression</title>
      <link>/publication/2024_alternative_promoter/</link>
      <pubDate>Sun, 09 Jun 2024 00:00:00 +0000</pubDate>
      
      <guid>/publication/2024_alternative_promoter/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Applications of Artificial Intelligence in Biotechnology and Medicine</title>
      <link>/post/ai_biotech_medicine/</link>
      <pubDate>Thu, 22 Feb 2024 00:00:00 +0000</pubDate>
      
      <guid>/post/ai_biotech_medicine/</guid>
      <description>&lt;p&gt;Artificial Intelligence (AI) or Machine learning (ML) combines computer science with statistics and enables computers to learn from data and make decisions or predictions without being explicitly programmed to do so. AI has revolutionized numerous sectors within biotechnology, here I will highlight a few notable applications specifically in genomics and medicine.&lt;/p&gt;
&lt;p&gt;All living organisms store their genetic instructions in Deoxyribonucleic acid (DNA), built from the same four building blocks (nucleotides) but arranged in different sequential combinations. DNA contains the biological instructions, while proteins carry out the functions encoded within it. DNA sequencing technology enables the identification of the sequential arrangement of DNA. With the rapid advancements in DNA sequencing technology, the cost of sequencing has plummeted to less than 1000 US Dollars per human genome. Consequently, more and more genomes are being sequenced and there has been a remarkable expansion in the volume of publicly available DNA sequencing data. A new scientific discipline emerged to extract valuable insights from this vast amount of data: Bioinformatics. It integrates principles from both biology and information technology to enhance our understanding of biological processes.&lt;/p&gt;
&lt;h2 id=&#34;why-ai-is-required-in-genomics&#34;&gt;Why AI is required in genomics?&lt;/h2&gt;
&lt;p&gt;Genomics data is vast and complex, encompassing multi-omics data of the genome, transcriptome, proteome, and epigenome. These datasets offer complementary insights into biological systems, forming intricate hierarchical relationships, often nonlinear. Moreover, the precise mechanisms governing gene regulation still need to be explained.&lt;/p&gt;
&lt;p&gt;The declining cost of sequencing has enabled measuring many data points per patient for a large patient population. AI algorithms have emerged as powerful tools for processing and analyzing large-scale datasets, extracting meaningful patterns, and revealing correlations that may elude traditional statistical approaches. They can predict outcomes, classify sequences, and identify patterns within genomic data. This capability is essential for tasks such as identifying disease markers, predicting patient responses to treatments, and classifying genetic mutations. AI techniques enable the integration and analysis of diverse omics datasets to gain a comprehensive understanding of biological systems and diseases.&lt;/p&gt;
&lt;p&gt;Fueled by the explosion of biological data, all major biotech and pharma companies are embracing bioinformatics and AI to accelerate and optimize their research efforts. Moreover, major global IT companies such as Google, IBM, Microsoft, and Amazon have dedicated workforces in genomics and medicine working on AI-based technologies.&lt;/p&gt;
&lt;h2 id=&#34;applications-of-ai-in-genomics-and-medicine&#34;&gt;Applications of AI in genomics and medicine&lt;/h2&gt;
&lt;p&gt;One of the most prominent applications of AI in genomics is in genome sequence analysis. Sequencing technologies generate massive amounts of data, which require sophisticated computational approaches to analyze and interpret. AI algorithms, such as deep learning, can identify patterns within these large datasets. For example, Oxford Nanopore’s Guppy [1] leverages a deep learning model to translate the raw electronic signal generated by its DNA sequencer into bases. Google’s DeepVariant [2] uses a deep learning model to call genetic variants from high-throughput DNA sequencing data with higher accuracy than traditional methods. By accurately identifying variations in genomic sequences, researchers can better understand genetic predispositions to diseases and develop more personalized medical treatments.&lt;/p&gt;
&lt;p&gt;Another impactful application of AI in genomics lies in disease prediction. By analyzing large datasets of patients&amp;rsquo; genetic information and medical records, AI algorithms can identify patterns that associate specific genetic variants with an increased risk of developing certain diseases. For example, in oncology, AI models are being trained to predict a patient&amp;rsquo;s risk of developing specific cancers based on their genetic profile [3]. Using DNA obtained from blood samples, AI algorithms can predict if the patient has cancer or not [4]. This information can then be used for early detection and intervention, potentially saving lives.&lt;/p&gt;
&lt;p&gt;AI has completely revolutionized the drug discovery and development process. AI techniques are used at various stages, from target identification and lead optimization to clinical trial design and patient stratification. Analyzing vast libraries of potential drug molecules and their interactions with biological targets is a daunting task. However, AI algorithms can efficiently sift through this data, identifying promising candidates with the desired properties. This not only accelerates the drug discovery process but also increases the likelihood of finding effective treatments. Using multi-omics profiles from patients, AI models can also predict if a patient will respond to a drug treatment [5,6]. These AI models can potentially help clinicians in appropriate treatment selection and further accelerate aid in precision medicine.&lt;/p&gt;
&lt;p&gt;Antibody-based therapies have gained prominence in the treatment of various diseases, including cancer and autoimmune disorders. AI algorithms can analyze the structural and sequence data of antibodies to predict their binding affinity and selectivity, facilitating the design of antibodies with enhanced therapeutic properties [7]. Many biotech and pharma industries have resorted to AI to engineer desired antibodies for potential therapeutics or vaccines.&lt;/p&gt;
&lt;p&gt;AI has emerged as a powerful tool in the field of protein structure prediction, revolutionizing our ability to accurately predict the three-dimensional structures of proteins from their amino acid sequences. This capability is crucial for understanding protein function, drug discovery, and the design of novel therapeutics. AI algorithms have been applied across various stages of protein structure prediction, from tertiary structure prediction to protein-protein interaction modeling, offering significant advancements in accuracy and efficiency. For instance, DeepMind&amp;rsquo;s AlphaFold [8] project uses AI to predict the 3D structure of proteins using the information of amino acid sequences of the protein alone. AlphaFold has generated structural predictions for millions of proteins, many of which remain undiscovered through other experimental or computational means. This represents perhaps the most significant contribution AI has made to biology, with profound implications for medicine, especially in the imminent advancement of drug development.&lt;/p&gt;
&lt;p&gt;Recent advances in generative AI have also impacted biology and medicine to a greater extent. Generative AI refers to a class of AI algorithms that are designed to generate new content or data that is similar to, but not identical to, existing data. These powerful algorithms are developed by training on expansive datasets, during which they assimilate the fundamental patterns, connections, and frameworks inherent in the data. Essentially, they master the “language” or core patterns that define the underlying data. Using generative AI, scientists can create molecular structures of a novel compound that potentially inhibits the function of a protein of interest and be used for disease treatment [9]. Using generative AI, scientists can also engineer a new protein with a desired function [10]. Furthermore, generative AI has shown promise in personalized medicine by analyzing large-scale genomic and clinical datasets to tailor treatments to individual patients. By leveraging generative models, researchers can simulate the effects of different treatments on patient outcomes, guiding healthcare professionals in making more informed decisions. For example, large language models (LLMs) like OpenAI’s ChatGPT and Google’s PaLM2 are actively trained on vast repositories of patient clinical health records, facilitating researchers in gaining deeper insights into health, disease, and treatment modalities.&lt;/p&gt;
&lt;p&gt;In summary, the applications of AI in biotechnology and medicine are diverse and far-reaching. The convergence of AI and genomics has ignited a revolution in healthcare, ushering in an era of personalized medicine and accelerated drug discovery. From deciphering complex genetic data to predicting disease risk and designing targeted therapies, AI is unlocking the immense potential of genomics for the betterment of human health. As research in this field continues to evolve at an unprecedented pace, we can anticipate even more transformative applications in the years to come.&lt;/p&gt;
&lt;h2 id=&#34;references&#34;&gt;References&lt;/h2&gt;
&lt;ol&gt;
&lt;li&gt;Wick, R. R., Judd, L. M. &amp;amp; Holt, K. E. Performance of neural network basecalling tools for Oxford Nanopore sequencing. Genome Biol 20, 129 (2019).&lt;/li&gt;
&lt;li&gt;Poplin, R. et al. A universal snp and small-indel variant caller using deep neural networks. Nat Biotechnol 36, 983 (2018).&lt;/li&gt;
&lt;li&gt;Moon, I. et al. Machine learning for genetics-based classification and treatment response prediction in cancer of unknown primary. Nat Med 29, 2057–2067 (2023).&lt;/li&gt;
&lt;li&gt;Cristiano, S. et al. Genome-wide cell-free DNA fragmentation in patients with cancer. Nature 570, 385–389 (2019).&lt;/li&gt;
&lt;li&gt;Sharifi-Noghabi, H., Zolotareva, O., Collins, C. C. &amp;amp; Ester, M. MOLI: Multi-omics late integration with deep neural networks for drug response prediction. in Bioinformatics vol. 35 i501–i509 (Oxford University Press, 2019).&lt;/li&gt;
&lt;li&gt;Sharifi-Noghabi, H., Peng, S., Zolotareva, O., Collins, C. C. &amp;amp; Ester, M. AITL: Adversarial inductive transfer learning with input and output space adaptation for pharmacogenomics. Bioinformatics 36, I380–I388 (2020).&lt;/li&gt;
&lt;li&gt;Graves, J. et al. A Review of Deep Learning Methods for Antibodies. Antibodies (Basel) 9, (2020).&lt;/li&gt;
&lt;li&gt;Jumper, J. et al. Highly accurate protein structure prediction with AlphaFold. Nature 596, 583–589 (2021).&lt;/li&gt;
&lt;li&gt;Jiang, P. et al. Big data in basic and translational cancer research. Nat Rev Cancer 22, 625–639 (2022).&lt;/li&gt;
&lt;li&gt;Madani, A. et al. Large language models generate functional protein sequences across diverse families. Nat Biotechnol 41, 1099–1106 (2023).&lt;/li&gt;
&lt;/ol&gt;
</description>
    </item>
    
    <item>
      <title>The genomic and epigenomic landscape of double-negative metastatic prostate cancer</title>
      <link>/publication/2023_dnpc/</link>
      <pubDate>Thu, 08 Jun 2023 00:00:00 +0000</pubDate>
      
      <guid>/publication/2023_dnpc/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Beyond Reconstruction: What Leads to Satisfaction in Post-Disaster Recovery?</title>
      <link>/publication/2023_happiness/</link>
      <pubDate>Sat, 18 Mar 2023 00:00:00 +0000</pubDate>
      
      <guid>/publication/2023_happiness/</guid>
      <description></description>
    </item>
    
    <item>
      <title>The 5-Hydroxymethylcytosine Landscape of Prostate Cancer</title>
      <link>/publication/2022_prostate5hmc/</link>
      <pubDate>Wed, 02 Nov 2022 00:00:00 +0000</pubDate>
      
      <guid>/publication/2022_prostate5hmc/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Raunak Shrestha receives Todd Boehly - Prostate Cancer Foundation Young Investigator Award - 2022</title>
      <link>/post/pcfyi_2022/</link>
      <pubDate>Thu, 27 Oct 2022 00:00:00 +0000</pubDate>
      
      <guid>/post/pcfyi_2022/</guid>
      <description>&lt;p&gt;The Prostate Cancer Foundation (PCF) today announced the Class of 2022 Young Investigator Award recipients totaling $7.2 million in funding for innovative prostate cancer research.&lt;/p&gt;
&lt;p&gt;PCF Young Investigator Awards are intended to identify a cohort of future research leaders who will keep the field of prostate cancer research vibrant with new ideas and offer career and project support for early career physicians and scientists who are committed to advancing the prostate cancer field. Thirty-four PCF Young Investigator Awards totaling $7.2 million were granted to the promising next generation of cancer researchers.&lt;/p&gt;
&lt;p&gt;Raunak Shrestha, PhD was one of the PCF-Young Investigator awardee. His research award was generously sponsored by &lt;a href=&#34;https://en.wikipedia.org/wiki/Todd_Boehly&#34;&gt;Mr. Todd Boehly&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;&lt;a href=&#34;https://www.pcf.org/c/young-investigator-award-class-of-2022/&#34;&gt;&lt;strong&gt;PCF-Young Investigator Class of 2022&lt;/strong&gt;&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;&lt;img alt=&#34;png&#34; src=&#34;./pcfyi_webshot.png&#34;&gt;&lt;/p&gt;
&lt;p&gt;&lt;img alt=&#34;png&#34; src=&#34;./banner.png&#34;&gt;&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>Predicting Cancer Drug TARGETS - TreAtment Response GlmnET Signatures</title>
      <link>/publication/2021_target/</link>
      <pubDate>Tue, 21 Sep 2021 00:00:00 +0000</pubDate>
      
      <guid>/publication/2021_target/</guid>
      <description></description>
    </item>
    
    <item>
      <title>An integrated functional and clinical genomics approach reveals genes driving aggressive metastatic prostate cancer</title>
      <link>/publication/2021_prostatecrispr/</link>
      <pubDate>Fri, 30 Jul 2021 00:00:00 +0000</pubDate>
      
      <guid>/publication/2021_prostatecrispr/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Multiomics Characterization of Low-grade Serous Ovarian Carcinoma Identifies Potential Biomarkers of MEK-inhibitor Sensitivity and Therapeutic Vulnerability</title>
      <link>/publication/2021_lgsoc/</link>
      <pubDate>Thu, 14 Jan 2021 00:00:00 +0000</pubDate>
      
      <guid>/publication/2021_lgsoc/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Autoantibody landscape in patients with advanced prostate cancer</title>
      <link>/publication/2020_prostateab/</link>
      <pubDate>Wed, 23 Sep 2020 00:00:00 +0000</pubDate>
      
      <guid>/publication/2020_prostateab/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Identification of Conserved Evolutionary Trajectories in Tumors</title>
      <link>/publication/2020_conett/</link>
      <pubDate>Mon, 13 Jul 2020 00:00:00 +0000</pubDate>
      
      <guid>/publication/2020_conett/</guid>
      <description>&lt;!-- raw HTML omitted --&gt;
</description>
    </item>
    
    <item>
      <title>Well-Differentiated Papillary Mesothelioma of the Peritoneum is Genetically Distinct from Malignant Mesothelioma</title>
      <link>/publication/2020_wdpm/</link>
      <pubDate>Sat, 13 Jun 2020 00:00:00 +0000</pubDate>
      
      <guid>/publication/2020_wdpm/</guid>
      <description>&lt;!-- raw HTML omitted --&gt;
</description>
    </item>
    
    <item>
      <title>Group segmentation and heterogeneity in the choice of cooking fuels in post-earthquake Nepal</title>
      <link>/publication/2020_cookingfuel/</link>
      <pubDate>Sat, 16 May 2020 00:00:00 +0000</pubDate>
      
      <guid>/publication/2020_cookingfuel/</guid>
      <description></description>
    </item>
    
    <item>
      <title>यस्तो अवस्थामा आउँछ आरडीटी नेगेटिभ, पीसीआर पोजिटिभ</title>
      <link>/post/covid19_rdt_pcr_tests/</link>
      <pubDate>Thu, 16 Apr 2020 00:00:00 +0000</pubDate>
      
      <guid>/post/covid19_rdt_pcr_tests/</guid>
      <description>&lt;p&gt;&lt;a href=&#34;https://nepalkhabar.com/opinion/24707-2020-04-16-11-04-15&#34;&gt;Article Published in NepalKhabar April 16, 2020. बैशाख ४, २०७७&lt;/a&gt;&lt;/p&gt;
&lt;blockquote&gt;
&lt;p&gt;कोरोना भाइरस पहिचानका लागि नेपालमा नमुना संकलनको क्रम बढाउँदै लगिए पनि त्यस अनुपातमा परीक्षण बढाउन सकिएको छैन। यसकाे मुख्य कारण हाे- नेपालमै भएका प्रयोगशाला, उपकरण र दक्ष प्राविधिज्ञको पूर्ण सदुपयोग गर्न नसक्नु।&lt;/p&gt;
&lt;/blockquote&gt;
&lt;p&gt;अहिले नेपालसहित विश्वका २ सयभन्दा बढी मुलुकमा कोरोना भाइरस (कोभिड-१९) को संक्रमण फैलिएको छ। चीनबाट सुरु भएको यो महामारीको केन्द्र पछिल्लो समय युरोप र अमेरिका बनेका छन्। नेपालमा पनि स्थानीय स्तरमा एक महिला संक्रमित भएसँगै यो महामारी दोस्रो चरणमा प्रवेश गरेको छ।&lt;/p&gt;
&lt;p&gt;केही दिनयता निरन्तर संक्रमित भेटिन थालेका छन्। यसर्थ कोरोनाविरुद्ध थप सतर्कता अपनाउन र परीक्षण तीव्र पार्न आवश्यक छ। नेपाल सरकारले कोभिड-१९ को संक्रमण पत्ता लगाउन र्‍यापिड  डायग्नस्टिक टेस्ट (आरडीटी) र पीसीआर दुवै विधि अपनाएको छ।&lt;/p&gt;
&lt;p&gt;वैज्ञानिक नाम सार्स-कोभ-२ भाइरसको संक्रमण जाँच्ने दुई तरिका छन्: र्‍यापिड डायग्नस्टिक टेस्ट (आरडीटी) र पोलिमरेज चेन रियाक्सन (पीसीआर) टेस्ट। आरडीटी- व्यक्ति वा समुदायमा भाइरस संक्रमण छ कि छैन भनेर गरिने परीक्षण हो। कसैमा भाइरस संक्रमण भएमा उसको शरीरभित्र भाइरससँग लड्न रोग-प्रतिरोधात्मक एन्टिबडी प्रोटिन (आईजीएम र आईजीजी) उत्पादन हुन्छन्। यही एन्टिबडी प्रोटिनको मद्दतले ऊ आफैँ ठीक पनि हुन सक्छ। भविष्यमा पनि यही एन्टिबडी प्रोटिनले कोरोना भाइरस संक्रमणको जोखिम कम गर्छ।&lt;/p&gt;
&lt;p&gt;तर आरडीटी परीक्षणले आजका दिनमा भाइरस संक्रमण छ वा छैन भन्ने सूचना दिन सक्दैन। पीसीआर विधिले भने कोरोना भाइरस छ वा छैन भन्ने जानकारी दिन सक्छ। नयाँ संक्रमण पहिचान गर्न सक्छ। यसका लागि मानिसको नाक वा घाँटी भित्रबाट नमुना (तरल पदार्थ) लिइन्छ।&lt;/p&gt;
&lt;p&gt;नेपालमा प्रयोग भइरहेको आरडीटी विधिले मानिसको रगतमा एन्टिबडी प्रोटिन छ वा छैन भनी परीक्षण गर्छ। कसैमा भाइरस संक्रमण भएमा यो एन्डिबडी प्रोटिन बन्न केही दिन लाग्छ। भाइरस संक्रमण भएको ७ दिनदेखि ६ महिनासम्म (वा योभन्दा पनि बढी) यो एन्डिबडी प्रोटिन मानिसको रगतमा रहिरन्छ। रगतमा यो एन्डिबडी प्रोटिन देखिए, आरडीटी परीक्षणको नतिजा पोजिटिभ आउँछ।&lt;/p&gt;
&lt;p&gt;तर भाइरस संक्रमण भएको १ देखि ७ दिनसम्म आरडीटी परीक्षण गर्दा नतिजा नेगेटिभ आउँछ। किनभने यो भाइरस संक्रमणको प्रारम्भिक चरणमा शरीरभित्र भाइरस भए पनि रगतमा एन्डिबडी प्रोटिन बनिसकेको हुँदैन। त्यसैले आरडीटीमा नेगेटिभ देखिएका हरेक मानिसमा पीसीआर परीक्षण गर्न जरुरी हुन्छ। तर नेपालमा आरडीटीमा नेगेटिभ देखिएका मानिसमा कोभिड-१९ का लक्षण देखिए मात्र फेरि पीसीआर परीक्षण गर्ने गरिएको छ। यसले गर्दा धेरै जना संक्रमित पहिचान गर्नबाट छुटेका हुन सक्छन्।&lt;/p&gt;
&lt;p&gt;हालै वीरगन्जको क्वारेन्टिनमा रहेकी एक महिलालाई आरडीटी परीक्षण गर्दा नतिजा नेगेटिभ आएपछि आफ्नो घर कैलाली पठाइयो, तर फेरि पीसीआर परीक्षण गर्दा नतिजा पोजिटिभ आयो। यसको मतलब ती महिलामा भाइरस संक्रमणको प्रारम्भिक चरणमा थियो, जुन आरडीटीले पहिचान गर्न सकेन। पीसीआरले गर्‍याे।&lt;/p&gt;
&lt;p&gt;भाइरस संक्रमण भएको ७–२१ दिनभित्र आरडीटी परीक्षण गरियो भने नतिजा पोजिटिभ आउँछ। पीसीआर परीक्षण गर्दा पनि पोजिटिभै आउँछ। यसको अर्थ उसमा भाइरस भएको, संक्रमण मध्यम चरणमा रहेको र एन्डिबडी प्रोटिन पनि बनेको प्रमाणित हुन्छ। भाइरस संक्रमण भएको १४–२१ दिन बितिसकेको अवस्थामा आरडीटी परीक्षण गर्दा नतिजा पोजिटिभ आउँछ। तर पीसीआर परीक्षण गर्दा रिपोर्ट नेगेटिभ आउन सक्छ।&lt;/p&gt;
&lt;p&gt;यसको अर्थ उसमा हाल संक्रमण नरहेको वा निको हुने चरणमा रहेको भनी बुझ्न सकिन्छ। अहिले नेपालमा कतिपय स्थानमा भइरहेको पनि यही हो। आरडीटी गर्दा पोजिटिभ देखिन्छ भने पीसीआर गर्दा नेगेटिभ।&lt;/p&gt;
&lt;p&gt;हालै काठमाडौं पेप्सिकोलास्थित सनसिटी अपार्टमेन्टमा एकै परिवारका तीन जना (आमा, छोरा र बुहारी) बेलायतबाट कतार हुँदै काठमाडौं आएको करिब तीन साता बितिसकेको थियो। तीनै जनाको पहिले आरडीटीबाट परीक्षण गर्दा नतिजा पोजिटिभ देखियो, तर पुनः पीसीआर परीक्षण गर्दा आमा र छोरामा कोरोना देखियो भने बुहारीमा देखिएन। यसमा कुनै शंका नरहोस्, तीनै जना संक्रमित हुन्।&lt;/p&gt;
&lt;p&gt;आमा र छोराको शरीरभित्र अहिलेसम्म भाइरस छ, तर बुहारीको शरीरबाट हटिसकेको छ। बुहारीलाई विदेशमै भाइरस संक्रमण भएको र पछि उनीबाट आमा र छोरालाई सरेको (स्थानीय संक्रमण) हुन सक्छ। संक्रमित परिवारका सम्पर्कमा आएका मानिसको आरडीटीबाट परीक्षण गर्दा नतिजा नेगेटिभ आए पनि पुनः पीसीआर परीक्षण गर्न जरुरी छ।&lt;/p&gt;
&lt;p&gt;आरडीटी र पीसीआर दुवै परीक्षणमा नतिजा नेगेटिभ आए मात्र भाइरस संक्रमण नभएको पुष्टि हुन्छ।&lt;/p&gt;
&lt;table&gt;
&lt;thead&gt;
&lt;tr&gt;
&lt;th&gt;&lt;strong&gt;आरडिटी परिक्षण&lt;/strong&gt;&lt;/th&gt;
&lt;th&gt;&lt;strong&gt;पिसिआर परिक्षण&lt;/strong&gt;&lt;/th&gt;
&lt;th&gt;&lt;strong&gt;नतिजाको अर्थ&lt;/strong&gt;&lt;/th&gt;
&lt;/tr&gt;
&lt;/thead&gt;
&lt;tbody&gt;
&lt;tr&gt;
&lt;td&gt;नेगेटिभ&lt;/td&gt;
&lt;td&gt;पोजेटिभ&lt;/td&gt;
&lt;td&gt;भाइरस संक्रमण भएको १-७ दिन भित्र (प्रारम्भिक चरण) अवस्था, शरिरभित्र आजको दिनमा भाइरस रहेको अवस्था&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;पोजेटिभ&lt;/td&gt;
&lt;td&gt;पोजेटिभ&lt;/td&gt;
&lt;td&gt;भाइरस संक्रमण भएको ७-२१ दिन (मध्यम चरण) अवस्था, शरिरभित्र आजको दिनमा भाइरस रहेको अवस्था&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;पोजेटिभ&lt;/td&gt;
&lt;td&gt;नेगेटिभ&lt;/td&gt;
&lt;td&gt;भाइरस संक्रमण भएको १४-२१ दिन बितिसकिको अवस्था, शरिरबाट भाइरस हतिसकेको वा बिरामी निकोहुने चरणमा रहेको अवस्था&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;नेगेटिभ&lt;/td&gt;
&lt;td&gt;नेगेटिभ&lt;/td&gt;
&lt;td&gt;भाइरस संक्रमण नभएको अवस्था&lt;/td&gt;
&lt;/tr&gt;
&lt;/tbody&gt;
&lt;/table&gt;
&lt;p&gt;पीसीआरभन्दा आरडीटी परीक्षणको मूल्य धेरै सस्तो पर्छ। आरडीटी परीक्षणको नतिजा २०–२५ मिनेटभित्र निकाल्न सकिन्छ भने पीसीआर परीक्षणको नतिजा १–४ घण्टा लाग्छ। आरडीटी परीक्षण गर्न कुनै बिजुली वा महँगो उपकरण चाहिँदैन र साधारण तालिमप्राप्त ल्याब असिस्टेन्टले यो टेस्ट गर्न सक्छन्। त्यसैले आरडीटी परीक्षण गाउँगाउँमा ठूलो समुदायमा गर्न सकिन्छ। पीसीआर एउटा जटिल प्रविधि हो र यसका लागि सुविधाजनक प्रयोगशाला र विशिष्ट तालिमप्राप्त प्राविधिकको आवश्यकता पर्छ। त्यसैले पीसीआर परीक्षण सुगम क्षेत्रमा मात्र सम्भव छ।&lt;/p&gt;
&lt;h2 id=&#34;वजञन-परवधम-लगन-गरन-अवसर&#34;&gt;विज्ञान-प्रविधिमा लगानी गर्ने अवसर&lt;/h2&gt;
&lt;p&gt;नेपाल कोरोना भाइरस महामारीको दोस्रो चरणमा प्रवेश गरेको छ। यतिबेला नेपाल सरकारको पहिलो प्राथमिकता कोरोना भाइरस परीक्षण गरी संक्रमित पहिचान गर्नु हो। प्रारम्भिक दिनमा राष्ट्रिय जनस्वास्थ्य प्रयोगशाला (टेकु) मा मात्र पीसीआर परीक्षण हुन्थ्यो भने अहिले यो सेवा नेपालका ११ स्थानमा विस्तार भइसकेको छ। यो धेरै सकारात्मक कुरो हो। तर कोरोना भाइरस पहिचानका लागि नेपालमा नमुना संकलनको क्रम बढाउँदै लगिए पनि त्यस अनुपातमा परीक्षण बढाउन सकिएको छैन। यसकाे मुख्य कारण हाे- नेपालमै भएका प्रयोगशाला, उपकरण र दक्ष प्राविधिज्ञको पूर्ण सदुपयोग गर्न नसक्नु।&lt;/p&gt;
&lt;p&gt;नेपाल सरकारले हालै खरिद गरेको पीसीआर मेसिन प्रयोग गर्नुभन्दा धेरै अगाडिदेखि नेपालका विभिन्न अस्पताल, विश्वविद्यालय, सरकारी तथा गैरसरकारी र निजी अनुसन्धान केन्द्र गरी करिब २५ स्वास्थ्य संस्थामा अब्बल दर्जाका पीसीआर उपकरण थिए। यीमध्ये केही टेकुको राष्ट्रिय जनस्वास्थ्य प्रयोगशालामा हाल रहेका पीसीआर मेसिनजत्तिकै क्षमताका छन्। यी पीसीआर उपकरण नेपाल सरकारले खरिद गरेको भन्दा धेरै सस्ता पनि छन्। जुन पीसीआर उपकरण सरकारले तुरुन्तै प्रयोग गर्न पनि सक्छ।&lt;/p&gt;
&lt;p&gt;त्यसमाथि नेपालकै विभिन्न विश्वविद्यालयबाट बायोटेक्नोलोजी र मिक्रोबायोलोजीमा दिक्षित, पीसीआर प्रविधिमा तालिमप्राप्त सयौं अनुसन्धानकर्मी तथा प्राविधिज्ञलाई कोरोना भाइरसको परीक्षणमा सघाउन र यसको अध्ययन/अनुसन्धानमा लाग्न सरकारले आह्वान गर्न सक्छ। अमेरिका, बेलायत, जर्मनीजस्ता देशमा कोरोना भाइरसको परीक्षण त्यहाँको सरकारी प्रयोगशालाले मात्र धान्न नसकेर विभिन्न विश्वविद्यालय र निजी कम्पनीको प्रयोगशाला, उपकरण र प्राविधिज्ञलाई उपयोग गरिरहेका छन्।&lt;/p&gt;
&lt;p&gt;नेपाल सरकारले हालै खरिद गरेको पीसीआर उपकरण निकै कम क्षमताको भएको पाइएको छ। यो मेसिनले एकपटकमा एक बिरामीको मात्र नमुना परीक्षण गर्न मिल्छ। चौबीसै घण्टा निरन्तर काम गर्दा एक दिनमा जम्मा २४ बिरामीको मात्र नमुना परीक्षण गर्न मिल्ने देखिन्छ। तर राष्ट्रिय जनस्वास्थ्य प्रयोगशाला र नेपालका विभिन्न अनुसन्धान संस्थामा पहिलेदेखि रहेका पीसीआर उपकरणबाट एकैपटकमा ८०-९० बिरामीका नमुना परीक्षण गर्न सकिन्छ र सम्पूर्ण प्रक्रिया ३-४ घण्टामै सकिन्छ। चौबीसै घण्टा निरन्तर काम गरियाे भने एक दिनमा ४-५ सय बिरामीको नमुना परीक्षण गर्न मिल्छ। सरकारले देखाएको अदूरदर्शिताले कोरोना भाइरसको परीक्षणमा चाहिने सामग्री खरिद प्रक्रियामा नेपाली प्राज्ञिक तथा वैज्ञानिकसँग परामर्शै नगरेको स्पष्ट हुन्छ।&lt;/p&gt;
&lt;p&gt;पीसीआर एउटा महँगो प्रविधि र यसलाई सुविधाजनक प्रयोगशाला चाहिने हुन्छ। पीसीआर प्रविधि कोभिड-१९ बाहेक क्षयरोग, हैजा, मलेरिया, कालाजार, क्यान्सरजस्ता मानिसका रोग तथा पशुपक्षी र गहुँबालीमा लाग्ने रोग पहिचान गर्न पनि प्रयोग गरिन्छ।&lt;/p&gt;
&lt;p&gt;नेपाल सरकारले यसलाई खर्चभन्दा पनि विज्ञान-प्रविधिमा गरिने लगानीका रूपमा लिनुपर्छ। अहिल्यै पर्याप्त लगानी नगरे महामारीको अर्को चरणमा थेग्नै नसक्ने मूल्य चुकाउनुपर्छ। नेपाल विज्ञान-प्रविधिमा विश्व समुदायभन्दा धेरै पछि छ। तसर्थ यो महामारीलाई हामी विज्ञान-प्रविधिमा अधिकतम  लगानी गर्ने अवसरका रूपमा सदुपयोग गर्ने कि?&lt;/p&gt;
&lt;p&gt;(डा.श्रेष्ठ अमेरिकास्थित युनिभर्सिटी अफ क्यलिफोर्निया, सानफ्रानसिस्कोमा रिसर्च स्कलरका रूपमा क्यान्सर अनुसन्धानमा संलग्न छन्। साथै बायोटेक्नोलोजी सोसाईटी अफ नेपाल (बिएसएन) सँग पनि आबद्ध छन्।)&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>Y-box Binding Protein-1 is Crucial in Acquired Drug Resistance Development in Metastatic Clear-Cell Renal Cell Carcinoma</title>
      <link>/publication/2020_ybox/</link>
      <pubDate>Mon, 10 Feb 2020 00:00:00 +0000</pubDate>
      
      <guid>/publication/2020_ybox/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Identification of Predictive Gene Signature to Guide Precision Oncology of Clear-Cell Renal Cell Carcinoma</title>
      <link>/publication/2020_rcc/</link>
      <pubDate>Thu, 06 Feb 2020 00:00:00 +0000</pubDate>
      
      <guid>/publication/2020_rcc/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Pathway and network analysis of more than 2,500 whole cancer genomes</title>
      <link>/publication/2020_pcawg_network/</link>
      <pubDate>Wed, 05 Feb 2020 00:00:00 +0000</pubDate>
      
      <guid>/publication/2020_pcawg_network/</guid>
      <description></description>
    </item>
    
    <item>
      <title>BAP1 Haploinsufficiency Predicts a Distinct Immunogenic Class of Malignant Peritoneal Mesothelioma</title>
      <link>/publication/2019_mesothelioma/</link>
      <pubDate>Thu, 07 Feb 2019 00:00:00 +0000</pubDate>
      
      <guid>/publication/2019_mesothelioma/</guid>
      <description>&lt;!-- raw HTML omitted --&gt;
&lt;!-- raw HTML omitted --&gt;
</description>
    </item>
    
    <item>
      <title>Combinatorial Detection of Conserved Alteration Patterns for Identifying Cancer Subnetworks</title>
      <link>/publication/2019_cdcap/</link>
      <pubDate>Tue, 05 Feb 2019 00:00:00 +0000</pubDate>
      
      <guid>/publication/2019_cdcap/</guid>
      <description>&lt;!-- raw HTML omitted --&gt;
</description>
    </item>
    
    <item>
      <title>Visualization of Bibliography in my PhD Thesis</title>
      <link>/post/bibliography_phdthesis/</link>
      <pubDate>Sat, 01 Sep 2018 00:00:00 +0000</pubDate>
      
      <guid>/post/bibliography_phdthesis/</guid>
      <description>&lt;p&gt;I defended my PhD in Bioinformatics from the University of British Columbia (UBC) on August 2018. My PhD thesis can be accessed from the &lt;a href=&#34;http://hdl.handle.net/2429/66704&#34;&gt;UBC Library Collections&lt;/a&gt;. Here, I attempted to visualize bibliography in my PhD thesis. Hope you will find this interesting and useful.&lt;/p&gt;
&lt;p&gt;&lt;a href=&#34;/docs/citations/raunak_shrestha_ubc_phd_thesis_bibliography_2018.bib&#34;&gt;Download the bibliography (.bib) file&lt;/a&gt;&lt;/p&gt;
&lt;!-- raw HTML omitted --&gt;
&lt;p&gt;df20 &amp;lt;- df[1:20,]
df20&lt;!-- raw HTML omitted --&gt;&lt;!-- raw HTML omitted --&gt;&lt;/p&gt;
&lt;!-- raw HTML omitted --&gt;
&lt;!-- raw HTML omitted --&gt;
&lt;!-- raw HTML omitted --&gt;
&lt;!-- raw HTML omitted --&gt;
&lt;!-- raw HTML omitted --&gt;
&lt;!-- raw HTML omitted --&gt;
&lt;p&gt;I later post-processed the R-plots in Adobe Photoshop to get the figure below.
&lt;!-- raw HTML omitted --&gt;&lt;/p&gt;
&lt;p&gt;&lt;img alt=&#34;png&#34; src=&#34;./featured.png&#34;&gt;&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>Computational prioritization of cancer driver genes for precision oncology</title>
      <link>/publication/2018_phdthesis/</link>
      <pubDate>Thu, 09 Aug 2018 00:00:00 +0000</pubDate>
      
      <guid>/publication/2018_phdthesis/</guid>
      <description></description>
    </item>
    
    <item>
      <title>High-throughput detection of RNA processing in bacteria</title>
      <link>/publication/2018_rnabacteria/</link>
      <pubDate>Tue, 27 Mar 2018 00:00:00 +0000</pubDate>
      
      <guid>/publication/2018_rnabacteria/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Deep Genomic Signature for early metastasis prediction in Prostate Cancer</title>
      <link>/publication/2018_dgs/</link>
      <pubDate>Thu, 01 Mar 2018 00:00:00 +0000</pubDate>
      
      <guid>/publication/2018_dgs/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Ultra High-Dimensional Nonlinear Feature Selection for Big Biological Data</title>
      <link>/publication/2018_featureselection/</link>
      <pubDate>Mon, 08 Jan 2018 00:00:00 +0000</pubDate>
      
      <guid>/publication/2018_featureselection/</guid>
      <description></description>
    </item>
    
    <item>
      <title>HIT&#39;nDRIVE: Patient-Specific Multi-Driver Gene Prioritization for Precision Oncology</title>
      <link>/publication/2017_hitndrive/</link>
      <pubDate>Tue, 18 Jul 2017 00:00:00 +0000</pubDate>
      
      <guid>/publication/2017_hitndrive/</guid>
      <description>&lt;!-- raw HTML omitted --&gt;
&lt;!-- raw HTML omitted --&gt;
&lt;!-- raw HTML omitted --&gt;
&lt;!-- raw HTML omitted --&gt;
</description>
    </item>
    
    <item>
      <title>BIRC6-targeting as potential therapy for advanced, enzalutamide-resistant prostate cancer</title>
      <link>/publication/2016_birc6/</link>
      <pubDate>Fri, 23 Sep 2016 00:00:00 +0000</pubDate>
      
      <guid>/publication/2016_birc6/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Visualize and cluster one-mode projection of a bi-partite graph</title>
      <link>/post/projections/</link>
      <pubDate>Wed, 20 Apr 2016 00:00:00 +0000</pubDate>
      
      <guid>/post/projections/</guid>
      <description>&lt;p&gt;Genomic knowledge are often curated in the form of Genes. For example, a geneset of genes mapping to the chromosome locus chr8q24; a geneset of genes known to involve in DNA Repair Module, etc. Similarly, this data structure is also representative of patient-Genes data.&lt;/p&gt;
&lt;p&gt;This can be thought of as a bipartite graph representing relation between individual Module to a gene. Often bioinformaticians are interested to visualize if there is any kind of relation between the Modules. This problem can be modeled as the conversion of two-mode network (bipartite graph) to one-mode network of Modules and visualize the resulting one-mode network. Here, I attempt to demonstrate how this can be achieved using R.&lt;/p&gt;
&lt;p&gt;&lt;a href=&#34;https://github.com/raunakms/2D-TO-1D-Projection&#34;&gt;&lt;strong&gt;Details in github project&lt;/strong&gt;&lt;/a&gt;&lt;/p&gt;
&lt;!-- raw HTML omitted --&gt;
&lt;!-- raw HTML omitted --&gt;
&lt;p&gt;bip &amp;lt;- matrix(0, nrow=length(ids), ncol=length(genes), dimnames=list(ids, genes))&lt;/p&gt;
&lt;p&gt;list.genes &amp;lt;- str_split(df$Genes, &amp;quot;:&amp;quot;)
list.gene.index &amp;lt;- lapply(list.genes, function(x) which(colnames(bip) %in% x))&lt;/p&gt;
&lt;p&gt;for(i in 1:length(list.gene.index)){
bip[i,list.gene.index[[i]]] &amp;lt;- 1
}
return(bip)
}&lt;/p&gt;
&lt;p&gt;bip &amp;lt;- get.bip(dat)&lt;/p&gt;
&lt;p&gt;bip[1:5,1:5]&lt;!-- raw HTML omitted --&gt;&lt;!-- raw HTML omitted --&gt;&lt;/p&gt;
&lt;!-- raw HTML omitted --&gt;
&lt;!-- raw HTML omitted --&gt;
&lt;!-- raw HTML omitted --&gt;
&lt;!-- raw HTML omitted --&gt;
&lt;!-- raw HTML omitted --&gt;
&lt;pre&gt;&lt;code&gt;for(i in 1:nrow(dat)){
    a &amp;amp;lt;- rownames(dat)[i]
    
    for(j in 1:ncol(dat)){
        b &amp;amp;lt;- colnames(dat)[j]
        pcc.ab &amp;amp;lt;- dat[a,b] - 0.05
        
        conn.pairs.a &amp;amp;lt;- colnames(dat)[which(dat[a,] &amp;amp;gt;= pcc.ab)]
        conn.pairs.b &amp;amp;lt;- rownames(dat)[which(dat[,b] &amp;amp;gt;= pcc.ab)]
        
        conn.pairs.ab &amp;amp;lt;- length(union(conn.pairs.a,conn.pairs.b))
        n &amp;amp;lt;- nrow(dat)
        
        csi &amp;amp;lt;- 1 - (conn.pairs.ab/n)
        mat[i,j] &amp;amp;lt;- csi
    }
}
return(mat)
&lt;/code&gt;&lt;/pre&gt;
&lt;p&gt;}&lt;/p&gt;
&lt;p&gt;dat.csi &amp;lt;- get.csi(dat.pcc)
dat.csi[1:5,1:5]&lt;!-- raw HTML omitted --&gt;&lt;!-- raw HTML omitted --&gt;&lt;/p&gt;
&lt;!-- raw HTML omitted --&gt;
&lt;!-- raw HTML omitted --&gt;
&lt;!-- raw HTML omitted --&gt;
&lt;!-- raw HTML omitted --&gt;
&lt;!-- raw HTML omitted --&gt;
&lt;h1 id=&#34;set-vertex-attributes&#34;&gt;Set vertex attributes&lt;/h1&gt;
&lt;p&gt;V(g)$label &amp;lt;- V(g)$name
V(g)$label.color &amp;lt;- &amp;quot;black&amp;quot;
V(g)$label.cex &amp;lt;- .8
V(g)$label.dist &amp;lt;- 0.3
V(g)$label.family &amp;lt;- &amp;quot;Helvetica&amp;quot;
V(g)$frame.color &amp;lt;- &amp;quot;grey&amp;quot;&lt;/p&gt;
&lt;p&gt;E(g)$color &amp;lt;- rgb(.6,.6,0,E(g)$weight)
E(g)$width &amp;lt;- E(g)$weight * 5&lt;/p&gt;
&lt;h3 id=&#34;generate-graph-output-file&#34;&gt;Generate Graph Output File&lt;/h3&gt;
&lt;p&gt;file.graph.output &amp;lt;- &amp;quot;graph_projection.gml&amp;quot;
write_graph(graph=g, file=file.graph.output, format=&amp;quot;gml&amp;quot;)  &lt;!-- raw HTML omitted --&gt;&lt;!-- raw HTML omitted --&gt;&lt;/p&gt;
&lt;!-- raw HTML omitted --&gt;
&lt;!-- raw HTML omitted --&gt;
&lt;!-- raw HTML omitted --&gt;
&lt;!-- raw HTML omitted --&gt;
&lt;!-- raw HTML omitted --&gt;
&lt;p&gt;&lt;a href=&#34;https://github.com/raunakms/2D-TO-1D-Projection&#34;&gt;&lt;strong&gt;Details in github project&lt;/strong&gt;&lt;/a&gt;&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>Heterogeneity in the inter-tumor transcriptome of high risk prostate cancer</title>
      <link>/publication/2014_highriskpca/</link>
      <pubDate>Tue, 26 Aug 2014 00:00:00 +0000</pubDate>
      
      <guid>/publication/2014_highriskpca/</guid>
      <description></description>
    </item>
    
    <item>
      <title>A Meta-Analysis Approach for Characterizing Pan-Cancer Mechanisms of Drug Sensitivity in Cell Lines</title>
      <link>/publication/2014_drugresp/</link>
      <pubDate>Fri, 18 Jul 2014 00:00:00 +0000</pubDate>
      
      <guid>/publication/2014_drugresp/</guid>
      <description></description>
    </item>
    
    <item>
      <title>HIT&#39;nDRIVE: Multi-driver gene prioritization based on hitting time</title>
      <link>/publication/2014_hitndrive/</link>
      <pubDate>Tue, 01 Apr 2014 00:00:00 +0000</pubDate>
      
      <guid>/publication/2014_hitndrive/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Analysis of KatG Ser315Thr Mutation in Multidrug Resistant Mycobacterium tuberculosis and SLC11A1 Polymorphism in Multidrug Resistance Tuberculosis in Central Development Region of Nepal Using PCR-RFLP Technique: A Pilot Study</title>
      <link>/publication/2011_mtb/</link>
      <pubDate>Tue, 18 Jan 2011 00:00:00 +0000</pubDate>
      
      <guid>/publication/2011_mtb/</guid>
      <description></description>
    </item>
    
  </channel>
</rss>
